Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsA yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.
A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.
The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show
5.
How the skin cancer virus outperforms the replication of host cells.
1.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
2.
AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence
3.
Vaccines that can help prevent cancer
4.
Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment
5.
Quality of Life Through Maintaining Functional Independence During Chronic Hematologic Conditions
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Efficient Management of First line ALK-rearranged NSCLC - Part V
5.
Managing Common Side Effects During Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge